125 related articles for article (PubMed ID: 20722625)
1. Co-expression of recombinant human CYP2C9 with human cytochrome P450 reductase in protease deficient S. cerevisiae strain at a higher scale yields an enzyme of higher specific activity.
Rao KN; Suman SK; Kiran YR; Kuanr AR; Gupta AK; Bhalla K; Kumar V; Kundu P; Arora K; Soni R
Drug Metab Lett; 2010 Dec; 4(4):246-53. PubMed ID: 20722625
[TBL] [Abstract][Full Text] [Related]
2. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5.
Peyronneau MA; Renaud JP; Truan G; Urban P; Pompon D; Mansuy D
Eur J Biochem; 1992 Jul; 207(1):109-16. PubMed ID: 1628642
[TBL] [Abstract][Full Text] [Related]
3. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Locuson CW; Wienkers LC; Jones JP; Tracy TS
Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y
Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832
[TBL] [Abstract][Full Text] [Related]
5. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.
Kaspera R; Naraharisetti SB; Evangelista EA; Marciante KD; Psaty BM; Totah RA
Biochem Pharmacol; 2011 Sep; 82(6):681-91. PubMed ID: 21726541
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
Inui H; Maeda A; Ohkawa H
Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
[TBL] [Abstract][Full Text] [Related]
7. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
Crespi CL; Miller VP
Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
[TBL] [Abstract][Full Text] [Related]
8. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
[TBL] [Abstract][Full Text] [Related]
9. Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9.
Boye SL; Kerdpin O; Elliot DJ; Miners JO; Kelly L; McKinnon RA; Bhasker CR; Yoovathaworn K; Birkett DJ
Xenobiotica; 2004 Jan; 34(1):49-60. PubMed ID: 14742136
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome b5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4.
Zhang H; Hamdane D; Im SC; Waskell L
J Biol Chem; 2008 Feb; 283(9):5217-25. PubMed ID: 18086668
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
[TBL] [Abstract][Full Text] [Related]
12. Enzyme source effects on CYP2C9 kinetics and inhibition.
Kumar V; Rock DA; Warren CJ; Tracy TS; Wahlstrom JL
Drug Metab Dispos; 2006 Nov; 34(11):1903-8. PubMed ID: 16928789
[TBL] [Abstract][Full Text] [Related]
13. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
[TBL] [Abstract][Full Text] [Related]
14. A genetically engineered P450 monooxygenase: construction of the functional fused enzyme between rat cytochrome P450c and NADPH-cytochrome P450 reductase.
Murakami H; Yabusaki Y; Sakaki T; Shibata M; Ohkawa H
DNA; 1987 Jun; 6(3):189-97. PubMed ID: 3109864
[TBL] [Abstract][Full Text] [Related]
15. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
16. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a novel host, high-red yeast that stably expresses hamster NADPH-cytochrome P450 oxidoreductase: usefulness for examination of the function of mammalian cytochrome P450.
Ohgiya S; Goda T; Hoshino T; Kamataki T; Ishizaki K
Arch Biochem Biophys; 1997 Jul; 343(2):215-24. PubMed ID: 9224733
[TBL] [Abstract][Full Text] [Related]
18. P450 redox enzymes in the white rot fungus Phanerochaete chrysosporium: gene transcription, heterologous expression, and activity analysis on the purified proteins.
Subramanian V; Doddapaneni H; Syed K; Yadav JS
Curr Microbiol; 2010 Oct; 61(4):306-14. PubMed ID: 20221604
[TBL] [Abstract][Full Text] [Related]
19. The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome b(5).
Im SC; Waskell L
Arch Biochem Biophys; 2011 Mar; 507(1):144-53. PubMed ID: 21055385
[TBL] [Abstract][Full Text] [Related]
20. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli.
Vail RB; Homann MJ; Hanna I; Zaks A
J Ind Microbiol Biotechnol; 2005 Feb; 32(2):67-74. PubMed ID: 15739102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
